Results 171 to 180 of about 15,814 (215)

A rare case of incidental asymptomatic emphysematous cystitis in a patient taking empagliflozin. [PDF]

Urol Case Rep
Ali A, Sandoval V, Sharma N.
europepmc   +1 more source

Emerging Role of Sodium-Glucose Cotransporter-2 Inhibitors in Aortic Stenosis. [PDF]

JACC Basic Transl Sci
Mazur P, Kopytek M, Natorska J.
europepmc   +1 more source

Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trial. [PDF]

Cardiovasc Endocrinol Metab
Chen WS, Yang NI, Verma S, Liu MH, Chien KY, Chen CW, Quan A, Teoh H, Yan AT, Connelly KA, Juan YH, Chang CW, Mazer CD, Wang CH.   +13 more
europepmc   +1 more source

Empagliflozin in improving exercise tolerance in HFpEF: study protocol for an open-label, randomized controlled study. [PDF]

Trials
Huang R, Deng Y, Li M, Chen L, Lv M, Liao L, Ma L, Huang Z.   +7 more
europepmc   +1 more source

Sodium-Glucose Cotransporter 2 Inhibitors in Alport Syndrome: Emerging Clinical Evidence and Mechanistic Insights. [PDF]

Kidney360
Miyata KN, Miner JH.
europepmc   +1 more source

Early In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors After ST-Elevation Myocardial Infarction: A Clinical Review of Hemodynamic and Renal Safety. [PDF]

Rev Cardiovasc Med
Farhan M, Patel T, Almarouj D, Seyfi A, Abdi SIA, Abufanas A, Rimawi A, Al-Zuhairi I, Al-Zuhairi A, Al Azzawi A, Patel BD, Awosika A.   +11 more
europepmc   +1 more source

Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis.

Cardiorenal Med
Huang W, Guan T, Yan Z, Cui Y, Bi S, Wu M, Yuan D.   +6 more
europepmc   +1 more source

Targeting NLRP3 Inflammasomes in Myocarditis: Potential Therapeutic Strategies and Clinical Translation. [PDF]

Scientifica (Cairo)
Retnowati FD, Halawa DR, Maayah ZH, Abdallah AM.   +3 more
europepmc   +1 more source

Gliflozins in Practice: Real-Life Use of Dapagliflozin and Empagliflozin in HFrEF Versus Clinical Trial Data. [PDF]

Diagnostics (Basel)
Mapelli M, Caputo R, Valenti M, Rubbo FM, Salvioni E, Mattavelli I, Galotta A, Piotti A, Puttini F, Manfrin L, Vignati C, Costantino S, Agostoni P.   +12 more
europepmc   +1 more source

Empagliflozin Attenuates Cardiac Fibrosis by Suppressing Fibroblast-Mediated C-C Motif Chemokine Ligand 2 Expression. [PDF]

J Am Heart Assoc
Nakai E, Horitani K, Ogawa H, Wada K, Yura Y, Min KD, Morioka S, Suwa Y, Shiojima I.   +8 more
europepmc   +1 more source